Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
Millions of individuals worldwide suffer with dyspepsia, or heartburn. Stress and poor diets are increasing its frequency, affecting the market by increasing the demand for symptom alleviation and treatment options.
Recently, endoscopy, imaging, and breath testing have improved. Doctors can effectively diagnose and classify dyspepsia using these instruments. It becomes simpler to focus therapies and treat each patient, changing the market.
Dietary adjustments, over-the-counter antacids, proton pump inhibitors (PPIs), histamine receptor antagonists (H2RAs), and prokinetic medicines may cure dyspepsia. Meeting patient wants and preferences with these treatment alternatives affects the market.
Patient education initiatives regarding dyspepsia symptoms, causes, and management shift the market by encouraging early diagnosis, treatment adherence, and proactive medical care.
Healthcare access and cost vary, slowing market development, particularly in low-income countries. The market changes because patients' access to treatment, performance, and sales of therapeutic items are affected.
Tight dyspepsia drug approval and sales standards affect the market by ensuring safe, effective, and high-quality goods. These restrictions impact market competition and product development.
Developing economies offer enormous growth potential due to greater healthcare facilities and digestive disease expertise. This may increase investment, competition, and product demand, transforming the market.
Many pharmaceutical firms provide a variety of dyspepsia treatments. This strong rivalry influences market dynamics via pricing tactics and product differentiation.
More generic dyspepsia drugs are coming out, causing price competition and market saturation. This impacts price, market share, and product availability.
As medication transport systems, preparation technologies, and novel treatment modalities including gut microbiome-targeted medicines and neuromodulation improve, they drive innovation, improve efficacy, and establish trends.
Healthcare markets shift as patient-centered treatment and cooperative decision-making become increasingly crucial. It requires customized treatment plans, patient-reported outcomes evaluations, and patient participation, which change market preferences.
GERD, IBS, and peptic ulcers increase with dyspepsia. It affects their treatment and market. It promotes multi-management and market change.
Market trends are affected by healthcare expenditure, insurance coverage, and income. These variables affect how easily people can receive healthcare, how much they can spend, and how many pharmaceutical products are marketed. Market demand and growth change.
Public health policies and initiatives aim to reduce gastrointestinal problems, promote healthy lives, and make medical treatment simpler. These initiatives encourage early detection, preventative treatment, and full patient care, affecting market trends and product demand.
Research and development of novel dyspepsia medication targets, biomarkers, and treatments alter market dynamics. These efforts spur innovation, treatment recommendations, and pharmaceutical company competitiveness, which impacts market trends and product differentiation.
Telemedicine and digital health technologies for online discussions, patient monitoring, and illness management in dyspepsia care reform the market by enhancing treatment efficacy and patient access. This affects market trends and service delivery.
When pharma firms, medical device producers, and healthcare providers combine or create strategic collaborations, competition, product lines, and market share shift. Market trends and industrial operations evolve.
The market transforms when dyspepsia care uses AI, big data analytics, and wearable gear to monitor the condition, generate individualized treatment regimens, and include patients. This alters market and service patterns.
Dyspepsia Market Highlights:
Dyspepsia Market Scenario:
The Dyspepsia market is projected to reach USD 1.35 Billion by 2030 at 4.02% CAGR during the forecast period 2022-2030. Dyspepsia is a chronic medical condition, that causes discomfort in the upper abdomen of the patient due to indigestion. The gastrointestinal organs, the stomach and the small intestine (sometimes the esophagus), do not function normally. Gastrointestinal causes of dyspepsia are gastritis, peptic ulcers, gallstones, stomach cancer, constipation, reduced blood flow in the intestine (intestinal ischemia). Nongastrointestinal causes are diabetes, thyroid disease, kidney disease and consumption of drugs like nonsteroidal anti-inflammatory drugs (NSAIDs such as ibuprofen), antibiotics and others. Dyspepsia is also caused due to overeating, smoking and extreme consumption of alcohol. The increasing prevalence of digestive diseases is the key factor for the market to grow. According to the Centers for Disease Control and Prevention in 2016, 14.7 million people in the US suffered from digestive ulcers. Such a high prevalence of digestive diseases enhances the market growth during the forecast period. Other factors like growing caffeine intake, increasing alcohol consumption, rising prevalence of diabetes, increasing incidences of thyroid diseases and stomach cancer, robust R&D activities to develop new drugs and advancement in diagnosis and treatment technologies is driving the growth of the market.
However, factors such as expensive diagnosis test and intense competition among the major market players to gain maximum market share are expected to restrict the market growth during the forecast period.
Segmentation
The global dyspepsia market is segmented on the basis of diagnosis, treatment, and end-user. The dyspepsia market, by diagnosis, is sub-segmented into blood tests, breath tests, stool tests, endoscopy, X-ray, CT scan, and others. On the basis of treatment, the market is categorized into antacids, antibiotics, h2 blockers, proton pump inhibitors (PPIs), prokinetics, psychological therapies and others. Antacids are further sub-segmented into calcium carbonate, loperamide, simethicone, sodium bicarbonate and others. Antibiotics further sub-segmented into amoxicillin, clarithromycin, metronidazole, and others. H2 blockers are further categorized into cimetidine, famotidine, nizatidine, ranitidine, and others. Proton pump inhibitors (PPIs) is further segmented into esomeprazole, lansoprazole, and omeprazole. Prokinetics are categorized into bethanechol and metoclopramide. On the basis of end-user, the market is segmented into hospitals and clinics, ambulatory surgical centers, pharmacies, diagnostic centers and others.
On the basis of region, the market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas is sub-segmented into North America and South America. The North American region is further segmented into the U.S. and Canada. The European region is divided into two, namely, Western Europe and Eastern Europe. Western Europe is further classified into Germany, Italy, France, the U.K., Spain, and the rest of Western Europe. The Asia-Pacific region is sub-segmented into Japan, China, India, Australia, the Republic of Korea, and the rest of Asia-Pacific. The Middle Eastern and African region is sub-segmented into the United Arab Emirates, Saudi Arabia, Oman, Kuwait, Qatar, and the rest of the Middle East and Africa.
Key Players
- AstraZeneca
- GlaxoSmithKline
- Takeda Pharmaceutical Company
- Johnson & Johnson
- Eisai Co., Ltd
- Abbott Laboratories
- Salix Pharmaceuticals
- Bayer AG
- Boehringer Ingelheim GmbH
- Sanofi, Allergan Plc
Regional Market Summary
Global Dyspepsia Market Share (%), by Region, 2017
Sources: United European Gastroenterology, Cancer Research, the Centers for Disease Control and Prevention
The dyspepsia market is dominated by North America owing to rising prevalence of ulcerative colitis.
Ulcerative Colitis causes inflammation of the digestive tract which may lead to dyspepsia. According to the Centers for Disease Control and Prevention in 2015, 3 million people suffered from ulcerative colitis. Also, the increased adoption of technologically advanced devices and the high amount of healthcare expenditure drives the market growth in this region.
It is estimated that Europe stood second in the global dyspepsia market. Thus, increasing prevalence of chronic digestive disease in Europe contributes to market growth. According to the United European Gastroenterology report published in 2018, 365,000 deaths in Europe were due to digestive cancers. Also, rising healthcare expenditure and R&D activities are driving the growth of this market in Europe.
Asia-Pacific was projected to be the fastest growing region for the global dyspepsia market. Key factors such as rising number of patient population, increase in the adoption of minimally invasive surgeries, and rapid rise in endoscopy for the diagnosis and treatment of digestive diseases, influences the market in this region. Also, the rising medical tourism in countries like Malaysia, India, and Thailand drives market growth in this region.
The Middle East and Africa holds the least share of the global dyspepsia market due to the presence of stringent government policies and poor economies. However, increasing investment by private market players and growing government initiatives in this region can boost the market growth.
Market Segmentation and Key Market Players
Global Dyspepsia Market, by Diagnosis
- Blood Tests
- Breath Tests
- Stool Tests
- Endoscopy
- X-ray
- CT scan
- Others
Global Dyspepsia Market, by Treatment
- Antacids
- Calcium Carbonate
- Loperamide
- Simethicone
- Sodium Bicarbonate
- Others
- Antibiotics
- Amoxicillin
- Clarithromycin
- Metronidazole
- Others
- H2 Blockers
- Cimetidine
- Famotidine
- Nizatidine
- Ranitidine
- Others
- Proton Pump Inhibitors (PPIs)
- Esomeprazole
- Lansoprazole
- Omeprazole
- Prokinetics
- Bethanechol
- Metoclopramide
- Psychological Therapies
Global Dyspepsia Market, by End-User
- Hospitals and clinics
- Ambulatory surgical centers
- Pharmacies
- Diagnostic centers
- Others
Global Dyspepsia Market, by Region
- The Americas
- Europe
- Asia-Pacific
- Middle East & Africa
Intended Audience
- Pharmaceutical companies
- Biotechnological institutes
- Government and private laboratories
- Research and Development (R&D) companies
- Medical research laboratories
- Market research and consulting service providers
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
